Symbols / CRBP $10.48 +1.80% Corbus Pharmaceuticals Holdings, Inc.
CRBP Chart
About
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
Fundamentals
Scroll to Statements| Market Cap | 185.88M | Enterprise Value | 24.24M | Income | -78.54M | Sales | — | Book/sh | 8.38 | Cash/sh | 9.21 |
| Dividend Yield | — | Payout | 0.00% | Employees | 36 | IPO | — | P/E | — | Forward P/E | -2.15 |
| PEG | — | P/S | — | P/B | 1.25 | P/C | — | EV/EBITDA | -0.28 | EV/Sales | — |
| Quick Ratio | 7.96 | Current Ratio | 8.07 | Debt/Eq | 1.11 | LT Debt/Eq | — | EPS (ttm) | -5.90 | EPS next Y | -4.88 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2026-05-05 | ROA | -32.90% | ROE | -54.18% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 17.74M | Shs Float | 12.74M | Short Float | 7.92% |
| Short Ratio | 5.36 | Short Interest | — | 52W High | 20.56 | 52W Low | 6.10 | Beta | 2.79 | Avg Volume | 205.42K |
| Volume | 319.68K | Target Price | $41.25 | Recom | Strong_buy | Prev Close | $10.29 | Price | $10.48 | Change | 1.80% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-10 | main | Oppenheimer | Outperform → Outperform | $57 |
| 2025-11-13 | main | RBC Capital | Outperform → Outperform | $53 |
| 2025-10-20 | main | Wedbush | Outperform → Outperform | $38 |
| 2025-10-20 | reit | HC Wainwright & Co. | Buy → Buy | $40 |
| 2025-09-17 | reit | HC Wainwright & Co. | Buy → Buy | $40 |
| 2025-08-06 | main | Oppenheimer | Outperform → Outperform | $53 |
| 2025-05-07 | main | RBC Capital | Outperform → Outperform | $58 |
| 2025-05-07 | main | Oppenheimer | Outperform → Outperform | $56 |
| 2025-05-07 | main | HC Wainwright & Co. | Buy → Buy | $40 |
| 2025-03-12 | reit | HC Wainwright & Co. | Buy → Buy | $50 |
| 2025-03-11 | main | Jefferies | Buy → Buy | $53 |
| 2025-02-28 | init | William Blair | — → Outperform | — |
| 2025-02-18 | reit | HC Wainwright & Co. | Buy → Buy | $75 |
| 2025-02-10 | reit | HC Wainwright & Co. | Buy → Buy | $75 |
| 2024-12-02 | init | Piper Sandler | — → Overweight | $35 |
| 2024-08-07 | reit | RBC Capital | Outperform → Outperform | $82 |
| 2024-08-07 | main | Oppenheimer | Outperform → Outperform | $88 |
| 2024-08-06 | reit | HC Wainwright & Co. | Buy → Buy | $80 |
| 2024-07-10 | reit | Oppenheimer | Outperform → Outperform | $80 |
| 2024-06-26 | init | B. Riley Securities | — → Buy | $85 |
- Corbus brings new cervical and head-neck cancer data to ASCO - Stock Titan Wed, 22 Apr 2026 12
- $CRBP stock is down 9% today. Here's what we see in our data. - Quiver Quantitative ue, 16 Dec 2025 08
- Mizuho Sees Strong Risk-Reward in Corbus Pharmaceuticals Holdings, Inc. (CRBP) Near Cash Value - Yahoo Finance Fri, 17 Apr 2026 13
- Two cancer trials move ahead after FDA aligns on Corbus plan - Stock Titan ue, 07 Apr 2026 07
- Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch Fri, 17 Apr 2026 21
- While institutions invested in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) benefited from last week's 12% gain, individual investors stood to gain the most - simplywall.st ue, 27 Jan 2026 08
- (CRBP) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily Fri, 03 Apr 2026 06
- $CRBP stock is down 23% today. Here's what we see in our data. - Quiver Quantitative Fri, 31 Oct 2025 07
- How Much Upside is Left in Corbus Pharmaceuticals (CRBP)? Wall Street Analysts Think 318.33% - Yahoo Finance Wed, 11 Mar 2026 07
- Corbus hits 240-patient milestone for oral obesity drug study - Stock Titan ue, 14 Apr 2026 12
- $CRBP stock is up 18% today. Here's what we see in our data. - Quiver Quantitative Mon, 09 Mar 2026 07
- Corbus Pharmaceuticals (NASDAQ: CRBP) resets CEO and CFO pay, severance and CIC terms - Stock Titan hu, 16 Apr 2026 20
- CORBUS PHARMACEUTICALS HLDGS ($CRBP) Releases Q4 2025 Earnings - Quiver Quantitative Mon, 09 Mar 2026 07
- If You Invested $1,000 in Corbus Pharmaceu (CRBP) - Stock Titan Sun, 22 Mar 2026 10
- Obesity drug from Corbus shows rapid weight loss in early trial - Stock Titan Wed, 18 Mar 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
85.31
+75.10%
|
48.72
+8.08%
|
45.08
+29.40%
|
34.84
|
| Research And Development |
|
70.09
+117.54%
|
32.22
+3.38%
|
31.17
+93.15%
|
16.14
|
| Selling General And Administration |
|
15.21
-7.78%
|
16.50
+18.61%
|
13.91
-25.61%
|
18.70
|
| General And Administrative Expense |
|
15.21
-7.78%
|
16.50
+18.61%
|
13.91
-25.61%
|
18.70
|
| Other Gand A |
|
15.21
-7.78%
|
16.50
+18.61%
|
13.91
-25.61%
|
18.70
|
| Total Expenses |
|
85.31
+75.10%
|
48.72
+8.08%
|
45.08
+29.40%
|
34.84
|
| Operating Income |
|
-85.31
-75.10%
|
-48.72
-8.08%
|
-45.08
-29.40%
|
-34.84
|
| Total Operating Income As Reported |
|
-85.31
-75.10%
|
-48.72
-8.08%
|
-45.08
-13.16%
|
-39.84
|
| EBITDA |
|
-78.30
-107.43%
|
-37.75
+5.87%
|
-40.10
-17.71%
|
-34.07
|
| Normalized EBITDA |
|
-78.30
-107.43%
|
-37.75
+5.87%
|
-40.10
-39.54%
|
-28.74
|
| Reconciled Depreciation |
|
0.23
-60.37%
|
0.59
-8.27%
|
0.64
-15.99%
|
0.76
|
| EBIT |
|
-78.54
-104.86%
|
-38.34
+5.91%
|
-40.75
-16.97%
|
-34.84
|
| Total Unusual Items |
|
—
|
—
|
0.01
+100.16%
|
-5.33
|
| Total Unusual Items Excluding Goodwill |
|
—
|
—
|
0.01
+100.16%
|
-5.33
|
| Special Income Charges |
|
—
|
—
|
0.00
+100.00%
|
-5.00
|
| Other Special Charges |
|
—
|
—
|
—
|
5.00
|
| Net Income |
|
-78.54
-95.32%
|
-40.21
+9.85%
|
-44.60
-5.33%
|
-42.35
|
| Pretax Income |
|
-78.54
-95.32%
|
-40.21
+9.85%
|
-44.60
-5.33%
|
-42.35
|
| Net Non Operating Interest Income Expense |
|
5.53
+24.58%
|
4.44
+299.77%
|
-2.22
-4.22%
|
-2.13
|
| Interest Expense Non Operating |
|
0.00
-100.00%
|
1.87
-51.48%
|
3.86
|
—
|
| Net Interest Income |
|
5.53
+24.58%
|
4.44
+299.77%
|
-2.22
-4.22%
|
-2.13
|
| Interest Expense |
|
0.00
-100.00%
|
1.87
-51.48%
|
3.86
|
—
|
| Interest Income Non Operating |
|
5.53
-12.38%
|
6.31
+285.76%
|
1.64
|
—
|
| Interest Income |
|
5.53
-12.38%
|
6.31
+285.76%
|
1.64
|
—
|
| Other Income Expense |
|
1.24
-69.48%
|
4.07
+51.08%
|
2.70
+150.12%
|
-5.38
|
| Other Non Operating Income Expenses |
|
1.24
-69.48%
|
4.07
+51.08%
|
2.70
+5627.65%
|
-0.05
|
| Gain On Sale Of Security |
|
—
|
—
|
0.01
+102.58%
|
-0.33
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-78.54
-95.32%
|
-40.21
+9.85%
|
-44.60
-5.33%
|
-42.35
|
| Net Income From Continuing Operation Net Minority Interest |
|
-78.54
-95.32%
|
-40.21
+9.85%
|
-44.60
-5.33%
|
-42.35
|
| Net Income From Continuing And Discontinued Operation |
|
-78.54
-95.32%
|
-40.21
+9.85%
|
-44.60
-5.33%
|
-42.35
|
| Net Income Continuous Operations |
|
-78.54
-95.32%
|
-40.21
+9.85%
|
-44.60
-5.33%
|
-42.35
|
| Normalized Income |
|
-78.54
-95.32%
|
-40.21
+9.85%
|
-44.60
-20.50%
|
-37.02
|
| Net Income Common Stockholders |
|
-78.54
-95.32%
|
-40.21
+9.85%
|
-44.60
-5.33%
|
-42.35
|
| Diluted EPS |
|
-5.90
-60.33%
|
-3.68
+64.31%
|
-10.31
-1.58%
|
-10.15
|
| Basic EPS |
|
-5.90
-60.33%
|
-3.68
+64.31%
|
-10.31
-1.58%
|
-10.15
|
| Basic Average Shares |
|
13.32
+22.00%
|
10.92
+152.23%
|
4.33
+3.76%
|
4.17
|
| Diluted Average Shares |
|
13.32
+22.00%
|
10.92
+152.23%
|
4.33
+3.76%
|
4.17
|
| Diluted NI Availto Com Stockholders |
|
-78.54
-95.32%
|
-40.21
+9.85%
|
-44.60
-5.33%
|
-42.35
|
| Total Other Finance Cost |
|
—
|
—
|
2.92
+37.14%
|
2.13
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
168.19
+7.90%
|
155.88
+451.35%
|
28.27
-57.37%
|
66.31
|
| Current Assets |
|
166.95
+9.14%
|
152.98
+549.69%
|
23.55
-60.87%
|
60.18
|
| Cash Cash Equivalents And Short Term Investments |
|
163.27
+9.53%
|
149.06
+613.01%
|
20.91
-64.68%
|
59.20
|
| Cash And Cash Equivalents |
|
28.49
+65.67%
|
17.20
+25.31%
|
13.72
-19.28%
|
17.00
|
| Cash Equivalents |
|
27.14
+123.36%
|
12.15
+25.33%
|
9.70
-26.54%
|
13.20
|
| Cash Financial |
|
1.35
-73.23%
|
5.05
+25.27%
|
4.03
+5.88%
|
3.81
|
| Other Short Term Investments |
|
134.78
+2.21%
|
131.86
+1736.03%
|
7.18
-82.98%
|
42.19
|
| Receivables |
|
—
|
—
|
—
|
—
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Restricted Cash |
|
0.67
+135.09%
|
0.28
+48.44%
|
0.19
-0.25%
|
0.19
|
| Other Current Assets |
|
3.02
-16.92%
|
3.63
+48.24%
|
2.45
+209.24%
|
0.79
|
| Total Non Current Assets |
|
1.24
-57.25%
|
2.90
-38.57%
|
4.73
-22.91%
|
6.13
|
| Net PPE |
|
1.24
-50.71%
|
2.52
-37.61%
|
4.04
-26.59%
|
5.50
|
| Gross PPE |
|
5.55
-15.84%
|
6.59
-13.18%
|
7.59
-11.63%
|
8.59
|
| Accumulated Depreciation |
|
-4.31
-5.72%
|
-4.07
-14.54%
|
-3.56
-14.96%
|
-3.09
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
1.13
+0.62%
|
1.13
-5.93%
|
1.20
-12.95%
|
1.38
|
| Other Properties |
|
1.08
-49.27%
|
2.13
-30.36%
|
3.06
-21.14%
|
3.88
|
| Leases |
|
3.33
+0.00%
|
3.33
+0.00%
|
3.33
+0.00%
|
3.33
|
| Other Non Current Assets |
|
—
|
0.39
-44.20%
|
0.69
+9.04%
|
0.63
|
| Total Liabilities Net Minority Interest |
|
20.69
+53.83%
|
13.45
-61.76%
|
35.18
+5.57%
|
33.32
|
| Current Liabilities |
|
20.69
+75.09%
|
11.82
-62.95%
|
31.89
+152.33%
|
12.64
|
| Payables And Accrued Expenses |
|
16.20
+104.13%
|
7.94
-44.15%
|
14.21
+138.88%
|
5.95
|
| Payables |
|
2.21
-53.72%
|
4.79
+50.55%
|
3.18
+46.23%
|
2.17
|
| Accounts Payable |
|
2.21
-53.72%
|
4.79
+50.55%
|
3.18
+46.23%
|
2.17
|
| Current Accrued Expenses |
|
13.98
+343.97%
|
3.15
-71.44%
|
11.03
+192.24%
|
3.77
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
2.86
+25.62%
|
2.28
-2.13%
|
2.33
+4.52%
|
2.22
|
| Current Debt And Capital Lease Obligation |
|
1.63
+1.68%
|
1.61
-90.90%
|
17.65
+298.34%
|
4.43
|
| Current Debt |
|
—
|
—
|
16.21
+414.74%
|
3.15
|
| Other Current Borrowings |
|
—
|
—
|
15.91
+469.02%
|
2.80
|
| Current Capital Lease Obligation |
|
1.63
+1.68%
|
1.61
+11.76%
|
1.44
+12.19%
|
1.28
|
| Other Current Liabilities |
|
—
|
—
|
0.04
+5.78%
|
0.04
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
-100.00%
|
1.63
-50.26%
|
3.28
-84.13%
|
20.68
|
| Long Term Debt And Capital Lease Obligation |
|
0.00
-100.00%
|
1.63
-49.58%
|
3.24
-84.32%
|
20.66
|
| Long Term Debt |
|
—
|
—
|
—
|
15.98
|
| Long Term Capital Lease Obligation |
|
0.00
-100.00%
|
1.63
-49.58%
|
3.24
-30.72%
|
4.68
|
| Other Non Current Liabilities |
|
—
|
—
|
0.04
+98.15%
|
0.02
|
| Stockholders Equity |
|
147.50
+3.56%
|
142.43
+2162.68%
|
-6.91
-120.93%
|
32.99
|
| Common Stock Equity |
|
147.50
+3.56%
|
142.43
+2162.68%
|
-6.91
-120.93%
|
32.99
|
| Capital Stock |
|
0.00
+100.00%
|
0.00
|
0.00
-100.00%
|
0.00
|
| Common Stock |
|
0.00
+100.00%
|
0.00
|
0.00
-100.00%
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
17.61
+44.60%
|
12.18
+175.32%
|
4.42
+6.05%
|
4.17
|
| Ordinary Shares Number |
|
17.61
+44.60%
|
12.18
+175.32%
|
4.42
+6.05%
|
4.17
|
| Additional Paid In Capital |
|
702.98
+13.52%
|
619.28
+44.09%
|
429.78
+1.08%
|
425.20
|
| Retained Earnings |
|
-555.43
-16.47%
|
-476.89
-9.21%
|
-436.68
-11.38%
|
-392.08
|
| Gains Losses Not Affecting Retained Earnings |
|
-0.05
-251.43%
|
0.04
+3600.00%
|
-0.00
+99.21%
|
-0.13
|
| Other Equity Adjustments |
|
-0.05
-251.43%
|
0.04
+3600.00%
|
-0.00
+99.21%
|
-0.13
|
| Total Equity Gross Minority Interest |
|
147.50
+3.56%
|
142.43
+2162.68%
|
-6.91
-120.93%
|
32.99
|
| Total Capitalization |
|
147.50
+3.56%
|
142.43
+2162.68%
|
-6.91
-114.10%
|
48.97
|
| Working Capital |
|
146.26
+3.62%
|
141.16
+1790.92%
|
-8.35
-117.56%
|
47.54
|
| Invested Capital |
|
147.50
+3.56%
|
142.43
+1430.83%
|
9.30
-82.15%
|
52.12
|
| Total Debt |
|
1.63
-49.58%
|
3.24
-84.49%
|
20.89
-16.76%
|
25.09
|
| Net Debt |
|
—
|
—
|
2.48
+16.63%
|
2.13
|
| Capital Lease Obligations |
|
1.63
-49.58%
|
3.24
-30.73%
|
4.68
-21.49%
|
5.96
|
| Net Tangible Assets |
|
147.50
+3.56%
|
142.43
+2162.68%
|
-6.91
-120.93%
|
32.99
|
| Tangible Book Value |
|
147.50
+3.56%
|
142.43
+2162.68%
|
-6.91
-120.93%
|
32.99
|
| Current Notes Payable |
|
—
|
0.00
-100.00%
|
0.30
-14.81%
|
0.35
|
| Interest Payable |
|
—
|
0.00
-100.00%
|
1.34
+46.50%
|
0.92
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-64.49
-54.31%
|
-41.79
-15.77%
|
-36.10
+3.85%
|
-37.54
|
| Cash Flow From Continuing Operating Activities |
|
-64.49
-54.31%
|
-41.79
-15.77%
|
-36.10
+3.85%
|
-37.54
|
| Net Income From Continuing Operations |
|
-78.54
-95.32%
|
-40.21
+9.85%
|
-44.60
-5.33%
|
-42.35
|
| Depreciation Amortization Depletion |
|
0.23
-60.37%
|
0.59
-8.27%
|
0.64
-15.99%
|
0.76
|
| Depreciation |
|
0.23
-60.37%
|
0.59
-8.27%
|
0.64
-56.92%
|
1.49
|
| Depreciation And Amortization |
|
0.23
-60.37%
|
0.59
-8.27%
|
0.64
-15.99%
|
0.76
|
| Other Non Cash Items |
|
-0.23
-139.15%
|
0.58
-27.33%
|
0.81
+8.42%
|
0.74
|
| Stock Based Compensation |
|
6.29
+2.33%
|
6.14
+77.09%
|
3.47
-39.33%
|
5.72
|
| Asset Impairment Charge |
|
—
|
—
|
—
|
0.00
|
| Operating Gains Losses |
|
—
|
—
|
-0.02
-102.72%
|
0.75
|
| Gain Loss On Investment Securities |
|
—
|
—
|
0.00
-95.95%
|
0.08
|
| Net Foreign Currency Exchange Gain Loss |
|
—
|
—
|
-0.02
-103.66%
|
0.65
|
| Gain Loss On Sale Of PPE |
|
—
|
—
|
0.00
-100.00%
|
0.02
|
| Change In Working Capital |
|
9.12
+263.56%
|
-5.58
-236.20%
|
4.09
+224.11%
|
-3.30
|
| Change In Receivables |
|
—
|
—
|
—
|
0.00
|
| Change In Prepaid Assets |
|
0.63
+151.59%
|
-1.23
+16.39%
|
-1.47
-193.43%
|
1.57
|
| Change In Payables And Accrued Expense |
|
9.04
+325.57%
|
-4.01
-166.15%
|
6.06
+239.26%
|
-4.35
|
| Change In Accrued Expense |
|
11.39
+302.99%
|
-5.61
-211.53%
|
5.03
+222.88%
|
-4.09
|
| Change In Payable |
|
-2.35
-246.54%
|
1.60
+55.93%
|
1.03
+500.26%
|
-0.26
|
| Change In Account Payable |
|
-2.35
-246.54%
|
1.60
+55.93%
|
1.03
+500.26%
|
-0.26
|
| Change In Other Working Capital |
|
—
|
—
|
—
|
—
|
| Change In Other Current Assets |
|
1.05
-7.97%
|
1.14
+49.48%
|
0.76
+24.05%
|
0.62
|
| Change In Other Current Liabilities |
|
-1.61
-8.44%
|
-1.48
-17.63%
|
-1.26
-10.74%
|
-1.14
|
| Investing Cash Flow |
|
-1.64
+98.65%
|
-121.31
-440.36%
|
35.64
+18.51%
|
30.07
|
| Cash Flow From Continuing Investing Activities |
|
-1.64
+98.65%
|
-121.31
-440.36%
|
35.64
+18.51%
|
30.07
|
| Net PPE Purchase And Sale |
|
-0.01
|
0.00
|
0.00
+100.00%
|
-0.01
|
| Purchase Of PPE |
|
-0.01
|
0.00
|
0.00
+100.00%
|
-0.01
|
| Sale Of PPE |
|
—
|
—
|
0.00
-100.00%
|
0.01
|
| Capital Expenditure |
|
-0.01
|
—
|
—
|
-0.01
|
| Net Investment Purchase And Sale |
|
-1.63
+98.65%
|
-121.31
-440.36%
|
35.64
+18.49%
|
30.08
|
| Purchase Of Investment |
|
-163.09
+9.80%
|
-180.80
-433.58%
|
-33.88
+60.75%
|
-86.34
|
| Sale Of Investment |
|
161.46
+171.38%
|
59.49
-14.43%
|
69.53
-40.28%
|
116.42
|
| Financing Cash Flow |
|
77.43
-53.52%
|
166.58
+6004.93%
|
-2.82
-428.66%
|
-0.53
|
| Cash Flow From Continuing Financing Activities |
|
77.43
-53.52%
|
166.58
+6004.93%
|
-2.82
-428.66%
|
-0.53
|
| Net Issuance Payments Of Debt |
|
0.00
+100.00%
|
-15.48
-438.62%
|
-2.87
-438.59%
|
-0.53
|
| Issuance Of Debt |
|
—
|
0.00
-100.00%
|
0.37
-79.66%
|
1.83
|
| Repayment Of Debt |
|
0.00
+100.00%
|
-15.48
-376.75%
|
-3.25
-37.14%
|
-2.37
|
| Long Term Debt Issuance |
|
—
|
0.00
-100.00%
|
0.37
-73.00%
|
1.38
|
| Long Term Debt Payments |
|
0.00
+100.00%
|
-15.48
-376.75%
|
-3.25
-116.36%
|
-1.50
|
| Net Long Term Debt Issuance |
|
0.00
+100.00%
|
-15.48
-438.62%
|
-2.87
-2315.13%
|
-0.12
|
| Short Term Debt Issuance |
|
—
|
—
|
0.37
-17.45%
|
0.45
|
| Short Term Debt Payments |
|
—
|
—
|
-0.43
+50.86%
|
-0.87
|
| Net Short Term Debt Issuance |
|
—
|
—
|
-0.05
+87.30%
|
-0.41
|
| Net Common Stock Issuance |
|
77.43
-57.47%
|
182.06
+343405.66%
|
0.05
|
0.00
|
| Net Other Financing Charges |
|
—
|
—
|
-0.19
|
—
|
| Changes In Cash |
|
11.29
+225.10%
|
3.47
+205.95%
|
-3.28
+59.03%
|
-8.00
|
| Beginning Cash Position |
|
17.87
+24.14%
|
14.39
-18.55%
|
17.67
-31.17%
|
25.68
|
| End Cash Position |
|
29.16
+63.21%
|
17.87
+24.14%
|
14.39
-18.55%
|
17.67
|
| Free Cash Flow |
|
-64.50
-54.32%
|
-41.79
-15.77%
|
-36.10
+3.88%
|
-37.56
|
| Interest Paid Supplemental Data |
|
0.00
-100.00%
|
2.82
+8.09%
|
2.61
+32.36%
|
1.97
|
| Amortization Of Securities |
|
-1.37
+58.94%
|
-3.33
-557.51%
|
-0.51
-505.21%
|
0.12
|
| Common Stock Issuance |
|
77.43
-57.47%
|
182.06
+343405.66%
|
0.05
|
0.00
|
| Issuance Of Capital Stock |
|
77.43
-57.47%
|
182.06
+343405.66%
|
0.05
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-16 View
- 8-K2026-04-14 View
- 8-K2026-04-07 View
- 10-K2026-03-09 View
- 8-K2026-03-09 View
- 42026-03-04 View
- 8-K2026-02-25 View
- 42026-02-18 View
- 42026-02-18 View
- 42026-02-18 View
- 42026-02-04 View
- 42026-02-04 View
- 42026-01-16 View
- 42026-01-16 View
- 42026-01-16 View
- 42026-01-16 View
- 8-K2026-01-12 View
- 8-K2025-12-18 View
- 42025-12-15 View
- 8-K2025-12-11 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|